Peter Noertersheuser

Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: A pilot study

Michael H. Weisman, Larry W. Moreland, Daniel E. Furst et al. · Clinical Therapeutics · 2003 · 297 citations

Rheumatoid Disorder, Rheumatology, Rheumatic Diseases +9

Population Pharmacokinetics of Upadacitinib Using the Immediate-Release and Extended-Release Formulations in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I–III Clinical Trials

Ben Klünder, Rajendar K. Mittapalli, Mohamed‐Eslam F. Mohamed et al. · Clinical Pharmacokinetics · 2019 · 59 citations · Full text

Impact of immunogenicity on pharmacokinetics, efficacy and safety of adalimumab in adult patients with moderate to severe chronic plaque psoriasis

Nael M. Mostafa, Ahmed Nader, Peter Noertersheuser et al. · Journal of the European Academy of Dermatology and Venereology · 2016 · 43 citations

Population Pharmacokinetics and Immunogenicity of Adalimumab in Adult Patients with Moderate-to-Severe Hidradenitis Suppurativa

Ahmed Nader, Denise Beck, Peter Noertersheuser et al. · Clinical Pharmacokinetics · 2017 · 36 citations

Autoimmune Disease, Allergy, Moderate-to-severe Hidradenitis Suppurativa +8

Three monthly doses of palivizumab are not adequate for 5-month protection: A population pharmacokinetic analysis

William V. La Via, Gerard Notario, Xiang‐Qing Yu et al. · Pulmonary Pharmacology & Therapeutics · 2013 · 30 citations · Full text

Asthma, Pediatric Lung Disease, Population Pharmacokinetic Analysis +17